The transgenic, fast-growing salmon was first developed in 1989.  The goal was simple, use fish genes to remove seasonal growth effects, with the hopes of creating a fish that could grow faster.  Faster growth means fewer resources to produce an equivalent amount or finished food product. This results in greater availability of a sustainable, consistent, high quality source of salmon, a great protein source with oils suggested to have positive roles in health.  However, the road to approval has been long. As the first GE animal, the AquaBounty salmon had navigated a complex regulatory maze, that now has finally allowed it to be produced and marketed in North America.  This episode speaks with Sylvia Wulf, CEO and President of AquaBounty Technologies.  We discuss the product, the regulatory situation, and when the products may be finally available to consumers.Follow AquaBounty on Twitter This is the AquaBounty website.# COLABRATalking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/# TALKING BIOTECHTwitter: https://twitter.com/talkingbiotechWebsite: https://www.colabra.app/podcasts/talking-biotech/Instagram: https://www.instagram.com/colabrahqThe Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.